07:00 , Aug 5, 2013 |  BC Week In Review  |  Clinical News

AMG 747: Development discontinued

Amgen disclosed in its 2Q13 earnings that it discontinued a Phase II program for AMG 747 to treat schizophrenia. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif.   Product: AMG 747   Business: Neurology   Molecular target: Glycine transporter...